Generation of adult human T-cell progenitors for immunotherapeutic applications - 05/04/18
![](/templates/common/images/mail.png)
Supported by the French National Institute of Health and Medical Research (INSERM), a European Research Council grant (ERC Regenerative Therapy, 269037), a European Union FP7 grant (CELL-PID, 261387), a European Union H2020 grant (SCIDNet, 666908), the Imagine Institute, an INCA-Plan Cancer grant (2009-2013), and a public grant overseen by the French National Research Agency (ANR) as part of the program “Investissements d'Avenir” (reference: ANR-10-IAHU-01). K.M. was funded by a China Scholarship Council (CSC). E.E. was funded by an INSERM-Plan Cancer fellowship. C.R. was funded by postdoctoral scholarships from the Deutsche Forschungsgemeinschaft (DFG). T.T. was funded by the Fund for Scientific Research Flanders (FWO Vlaanderen research projects G0B2913N). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. |
|
Disclosure of potential conflict of interest: C. Reimann's institution has received travel support from Bayer. The rest of the authors declare that they have no relevant conflicts of interest. |
Vol 141 - N° 4
P. 1491 - avril 2018 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?